Navigation Links
Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
Date:9/6/2008

Results Demonstrate Safety and Efficacy of First-in-Class Neurally Acting

Anti-Migraine Agent (NAAMA) for the Treatment of Acute Migraine

LONDON, Sept. 6 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), which unlike triptans, exhibits anti-migraine activity without causing vasoconstriction. COL-144 is a highly potent and selective 5HT1F receptor agonist. The studies were presented in poster presentations at the European Headache and Migraine Trust International Congress 2008 in London, Sept. 4-7, 2008.

"In the Phase II study, the majority of patients experienced migraine relief 20 to 40 minutes after dosing and COL-144 was generally well-tolerated," Alison Pilgrim, BM, BCh, DPhil, chief medical officer at CoLucid, said. "The study indicates that COL-144 may be a treatment option for all patients including those who don't respond to or are contraindicated for the current standard of care."

The randomized, double-blind study evaluated 130 migraine patients. Patients were not on prophylaxis and received 2.5 to 45 mg of COL-144 or placebo as an intravenous infusion over 20 minutes as first-line treatment of an acute migraine attack. The primary end-point parameter was headache response, defined as a reduction in headache severity from moderate to severe at baseline to mild or no headache at two hours after initiation of infusion of study drug.

A higher proportion of patients showed a headache response at two hours post dose in the 10 mg, 20 mg, 30 mg and 45 mg groups compared to placebo (54.2 to 75% vs. 45.2%) with a statistically significant linear association between response rates and
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 This BCC Research report ... of major players, market growth and size, and opportunities for ... and revenue through 2018. Patent analysis in the report focuses ... the U.S., Europe and ... - Define and discuss the global medical device technologies market. ...
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., a ... diagnosing and treating Autism Spectrum Disorders (ASD) announced today ... with The Research Foundation for The State University of ... provide a new biomarker to identify an abnormality in ... ASD. This biomarker is expected to be available for ...
(Date:9/18/2014)... Pharma IQ, after huge demand ... Countdown calendar to cover the years 2014 - 2018 ... shows the serialisation requirements around the globe and the ... For companies dealing with international markets, serialisation ... they will have to comply with new regulations coming ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company ... therapeutic agents for the treatment of Alzheimer,s and ... filed a response and request for continued examination ... 10/084,380, one of several applications pending in the ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... chief financial officer, will present an overview of the ... The VIVUS presentation will take place at the ... at 9:30 a.m. MST.  A live webcast and 30-day ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3
(Date:9/18/2014)... LEXINGTON, Ky (Sept. 17, 2014) -- Two independent ... PhD, of the University of Kentucky, and Charles ... published important studies exploring the role that a ... cardiovascular disease. , According to Whiteheart, previous genome-wide ... as a factor that regulates a protein called ...
(Date:9/18/2014)... release is available in German . ... host strategy not to fight a pathogen tooth and nail, but ... term. One key feature of tolerance is that the disease only ... host carries a high pathogen load. , Roland Regoes, a senior ... this approach to HIV. He set about investigating whether there are ...
(Date:9/18/2014)... CAMBRIDGE, Massachusetts, U.S.A., September 18, 2014 -- BGI ... sequencing service to Denmark-based DLF-Trifolium and the Department ... University in an effort to develop a series ... genomic selection (GS) methods. , GS is a ... contrast to the traditional QTL-based selection, uses information ...
(Date:9/18/2014)... September 18, 2014 CRDF Global ... first ever digital edition – rich with videos, ... of how CRDF Global empowers scientists and innovators ... of government, corporate, foundation and individual supporters, CRDF ... innovators in research, training and entrepreneurship. , The ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Research conducted ... Allegheny Health Network has documented improved survival ... surgical removal of the tumors along with stereotactic radiosurgery. ... of ASTRO (American Society for Radiation Oncology) ... uses numerous precisely focused radiation beams to treat tumors ...
Breaking Medicine News(10 mins):Health News:University of Kentucky research explores STXBP5 gene and its role in blood clotting 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:BGI Tech, DLF-Trifolium A/S, and Aarhus University applying genomic selection methods 2Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3
... to detect suspicious activity in airports, stadiums and other ... researcher who invented them to find and measure potentially ... professor of Computer Science and one of the world,s ... computer imaging, has received $400,000 from the National Institutes ...
... about the importance of eye assessments for babies during June,s ... 2 When should a parent schedule a comprehensive eye ... at 6 months, the average baby has reached a number ... the first eye and vision assessment. , , According ...
... for space headache to be established as a new ... astronauts, published in the June issue of Cephalalgia ... headaches are normally caused by space motion sickness, after ... no connection. "Our research shows that space flights ...
... device will facilitate single port access laparoscopic surgery , ... privately held biomaterials-based medical device company, announced today that ... and Drug Administration to market the InnoPort(TM) to facilitate ... The InnoPort is inserted into the abdomen to perform ...
... , - Free health clinics facing crisis of increasing demand, ... hand in helping make donation possible , , - ... banks in December , , RICHMOND, Va., June 2 ... announced today it is donating $1 million to free health ...
... ... at trial, and bring Attorneys state of the art fall prevention and protection training. ... (PRWEB) June ... settlements, assist representation at trial, and bring Attorneys state of the art fall prevention ...
Cached Medicine News:Health News:UCF researcher developing computer program to detect, measure brain tumors 2Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 2Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 3Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 4Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 5Health News:Researchers call for new space headache category following astronauts' survey 2Health News:Innovia Receives FDA Clearance For The InnoPort(TM) 2Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 2Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 3Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 4Health News:Fall Prevention/Protection - Slip and Fall Accredited Training for Legal Practices 2
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
... EVS has an ergonomic stapler ... mechanism which requires a single ... locks onto the target vessel ... site before, during and after ...
Medicine Products: